This functionality is implemented using Javascript. It cannot work without it, etc...

We are loading the information...

Skip to main content

Medical Policies

Medical policies are documents that define the plan coverage for technologies, procedures and treatments. The statements of medical necessity in the policies, about whether a technology, procedure, treatment, supply, equipment, drug or other service improves the health outcome of the population for which said technology or treatment was designed are based on scientific evidence, clinical studies and professional opinions from our providers and recognized medical organizations.

Each document displayed on this website is provided for informational purposes only and is not an authorization, explanation of benefits, or contract. Receiving benefits is subject to satisfaction of all terms and conditions of coverage. Medical technology is constantly changing, and we reserve the right to periodically review and update our policies.

ID Title Last Review Next Review Description Access
11.003.052 Molecular Markers in Fine Needle Aspirates of the Thyroid Jul 19, 2024 Sep 20, 2024 For individuals who have thyroid nodules without strong clinical or radiologic findings suggestive of... View
11.003.053 Whole Exome and Whole Genome Sequencing for Diagnosis of Genetic Disorders Apr 18, 2024 Apr 20, 2025 Standard whole exome sequencing, with trio testing when possible (see policy guidelines), may be considered... View
11.003.056 Genetic Testing for a Thalassemia Jul 10, 2024 Jul 20, 2025 Genetic testing to confirm a diagnosis of α-thalassemia is considered investigational. genetic testing... View
11.003.057 Genetic Testing for Fanconi Anemia Jan 08, 2024 Jan 20, 2025 Genetic testing for the diagnosis of fanconi anemia may be considered medically necessary when the... View
11.003.059 Genetic Testing for Hereditary Pancreatitis Mar 14, 2023 Mar 20, 2024 Genetic testing for hereditary pancreatitis may be considered medically necessary for patients aged 18 years... View
11.003.060  Genetic Testing for FLT3, NPM1, and CEBPA Variants in Cytogenetically Normal Acute Myeloid Leukemia Feb 20, 2024 Feb 20, 2025 Genetic testing for flt3 internal tandem duplication (flt3-itd), npm1, andcebpa variants may be considered... View
11.003.062 General Approach to Genetic Testing Jan 09, 2024 Jan 20, 2025 Genetic testing classified in one of the categories below may be considered medically necessary when all... View
11.003.063 BCR-ABL1 Testing in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia Nov 15, 2023 Nov 20, 2024 Chronic myelogenous leukemia bcr-abl1 qualitative testing for the presence of the fusion gene may be... View
11.003.064 Genetic Cancer Susceptibility Panels Using Next Generation Sequencing Jul 17, 2024 Nov 20, 2024 The human genome variation society nomenclature is used to report information on variants found in dna and... View
11.003.066 Genetic Testing for Duchenne and Becker Muscular Dystrophy Apr 17, 2024 Apr 20, 2025 Genetic testing for dmd gene variants may be considered medically necessary under the following conditions:... View
11.003.067 Genotype-Guided Warfarin Dosing Jul 08, 2024 Jul 20, 2025 Genotyping to determine cytochrome p450 2c9 (cyp2c9), p450 4f2 (cyp4f2), and vitamin k epoxide reductase... View
11.003.068 Genetic Testing for the Diagnosis of Inherited Peripheral Neuropathies Feb 13, 2024 Feb 20, 2025 Genetic testing is considered medically necessary when the diagnosis of an inherited peripheral motor or... View
11.003.069 Analysis of MGMT Promoter Methylation in Malignant Gliomas Jun 13, 2019 Policy Archived Methylation analysis of the o6-­methylguanine dna methyltransferase (mgmt) gene promoter from glioma tumor... View
11.003.070 Preimplantation Genetic Testing Sep 07, 2023 Sep 20, 2024 Preimplantation genetic diagnosis may be considered medically necessary as an adjunct to in vitro... View
11.003.072 Genetic Testing for Marfan Syndrome, Thoracic Aortic Aneurysms and Dissections, and Related Disorders Apr 19, 2024 Apr 20, 2025 Individual genetic testing for the diagnosis of marfan syndrome, ehlers-danlos syndrome type iv, other... View
11.003.073 Laboratory and Genetic Testing for Use of 5-Fluorouracil in Patients with Cancer Apr 15, 2024 Apr 20, 2025 Assay testing for determining 5-fluorouracil area under the curve in order to adjust 5-fluorouracil dose for... View
11.003.075 Proteomic Testing for Targeted Therapy in Non-Small-Cell Lung Cancer Dec 06, 2023 Dec 20, 2024 The use of proteomic testing, including but not limited to the veristrat assay, is considered investigational... View
11.003.076 Multibiomarker Disease Activity Blood Test for Rheumatoid Arthritis Jul 19, 2024 Jul 20, 2025 The use of a multibiomarker disease activity score for rheumatoid arthritis (eg, vectra score) is... View
11.003.077 LOS ENSAYOS DE VARIOS ALITOS CON EL ALISIS ALGORITMICO PARA PREDECIR EL RIESGO DE DABETES TIPO 2 Oct 11, 2016 Policy Archived El uso de paneles de varios analitos con el análisis algorítmico (masa) para la predicción de la diabetes... View
11.003.078 Noninvasive Prenatal Screening for Fetal Aneuploidies, Microdeletions, Single-Gene Disorders and Twin Zygosity Using Cell-Free Fetal DNA Apr 15, 2024 Apr 20, 2025 Nucleic acid sequencing-based testing of maternal plasma to screen for trisomy 21, 18, and 13 may be... View

Want to be up to date on topics like health, trending news, useful tips, lifestyles and more?

Subscribe to our blog and don't miss out on anything!

Subscribe to the blog

We want to personalize the content according to your preferences

Please select one or more categories to continue

Thanks for subscribing!

You will receive information of interest in your email.

787-277-6653 787-474-6326